scholarly journals Valuing new medicines in the early 21:st century

2017 ◽  
Vol 5 (1) ◽  
pp. 7-22
Author(s):  
Katarina Steen Carlsson ◽  
Bengt Jönsson
Keyword(s):  
Health Care ◽  
Clinical Practice ◽  
Real World ◽  
Patent Protection ◽  
New Technologies ◽  
New Technology ◽  
Treatment Strategies ◽  
Real World Data ◽  
Study Results ◽  
Pricing And Reimbursement

What is the actual value of new medicines? The answer to this question is the key to rational use of new technologies in health care and for design of appropriate incentives for innovation. In this paper we present methods, data and study results for valuing new medical technologies in a life cycle perspective, relevant for development of a new approach to contract and payment for innovation that can replace present systems for pricing and reimbursement.   Focus is on value in clinical practice, and on the data needs and methods needed for the development of outcome-based payment systems that balances risks and rewards for innovation in health care. We provide an overview of studies from the Swedish context on the value of new medicines introduced in the treatment of diabetes, cancer, cardiovascular disease and rheumatoid arthritis. These studies using national health data and quality registers emphasise the importance of continuing efforts to collect relevant data for assessment of value after a medicine reaches the market and starts to be used in clinical practice. It is only when medicines are used in clinical practice that the benefits for real-world patient populations can be identified, measured and valued. Analyses of real-world data will also assist further development and tailoring of treatment strategies to optimize the value of the new technology. While an effective patent system rewards innovation for a limited period of time, many innovations may continue to provide value to society long after patent protection, and these values must be included in the assessment of value of innovation.

Information technology in the evaluation of RWD / RWE (Real-World Data / Real-World Evidence)

2021 ◽  
Author(s):  
OV Zhukova ◽  
AL Khokholov
Keyword(s):  
Health Care ◽  
Information Technology ◽  
Clinical Practice ◽  
Clinical Efficacy ◽  
Real World ◽  
Information Technologies ◽  
Real World Data ◽  
Real World Evidence ◽  
Software Modules ◽  
Real Clinical Practice

The features of evaluating data from real clinical practice are discussed. Approaches to material processing for decision support in medicine and health care are also given. The development of standardized methods of analysis with the possibility of obtaining a unified indicator for assessing data from routine clinical practice, combined with the development of information technology is the direction of development of the concept of result-oriented health care. The classification of information technologies used in medicine and public health is presented. The main characteristics and functioning features of the developed software modules for automated data evaluation of real clinical practice are presented: a program for the distribution of drugs on the levels of clinical efficacy, a program to assess the effectiveness of therapy for the specified period; a program to determine the interval of clinical efficacy of drugs.

scholarly journals Costs Of Psychiatric Assistance (Pa) In A Brazilian Health Care Plan (Hp): A Real World Data Analysis

2014 ◽  
Vol 17 (3) ◽  
pp. A131
Author(s):  
Viana ADJR ◽  
AF Lopes ◽  
CP Matias ◽  
VP Moreira ◽  
JL Viana ◽  
...  
Keyword(s):  
Health Care ◽  
Data Analysis ◽  
Real World ◽  
Care Plan ◽  
Real World Data ◽  
World Data ◽  
Health Care Plan

Real-world data on initial treatment strategies for older adult patients with endometrial cancer in Japan

2019 ◽  
Vol 84 (5) ◽  
pp. 1051-1058
Author(s):  
Mayu Yunokawa ◽  
Shinsuke Sasada ◽  
Yae Takehara ◽  
Kenta Takahashi ◽  
Tatsunori Shimoi ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Older Adult ◽  
Real World ◽  
Initial Treatment ◽  
Treatment Strategies ◽  
Adult Patients ◽  
Real World Data ◽  
World Data

Real-World Data, Clinical Practice So Far

2021 ◽  
pp. 151-166
Author(s):  
Eleonora De Matteis ◽  
Raffaele Ornello ◽  
Simona Sacco
Keyword(s):  
Clinical Practice ◽  
Real World ◽  
Real World Data ◽  
World Data

Use of Real-World Data for advancing clinical practice

2020 ◽  
Vol 19 (s) ◽  
pp. 1-1
Author(s):  
K. Taraldsen ◽  
S. Mellone
Keyword(s):  
Clinical Practice ◽  
Real World ◽  
Real World Data ◽  
World Data

scholarly journals Mighty Mites

2005 ◽  
Vol 127 (09) ◽  
pp. 34-37
Author(s):  
Don W. Dareing ◽  
Thomas Thundat
Keyword(s):  
Health Care ◽  
Industrial Revolution ◽  
New Technologies ◽  
New Technology ◽  
Production Costs ◽  
New Materials ◽  
Performance Predictions ◽  
The 19Th Century ◽  
Analytical Tools ◽  
Reliability And Availability

This article reviews that the future belongs to machines built at molecular scales—if the tools to engineer them. Just as the steam engine sparked the industrial revolution of the 19th century, nanotechnology will likely ignite a new industrial revolution during the 21st century. Nanotechnology has the potential to impact all industries; the health care and computer industries are already capitalizing on it. New materials are being created that will affect everything from aerospace and energy to recreation and entertainment. Science is uncovering new technology almost daily, which will have a great impact on many aspects of society. These technologies are at various stages of development, but in the end, each spin-off product must withstand the test in the marketplace. The evaluation of each product will still be based on the same set of metrics as other products: performance, cost, risk or reliability, and availability. To satisfy these metrics, engineers will need analytical tools to make performance predictions, establish production costs and lifecycle economics, quantify the risk associated with new technologies, and satisfy a dynamic market.

A multi-layer cellular automata approach for algorithmic generation of virtual case studies: VIBe

2010 ◽  
Vol 61 (1) ◽  
pp. 37-45 ◽  
Author(s):  
R. Sitzenfrei ◽  
S. Fach ◽  
H. Kinzel ◽  
W. Rauch
Keyword(s):  
Boundary Conditions ◽  
Case Studies ◽  
Real World ◽  
New Technologies ◽  
Single Case ◽  
Software Tool ◽  
Simulation Software ◽  
Data Availability ◽  
Study Results

Analyses of case studies are used to evaluate new or existing technologies, measures or strategies with regard to their impact on the overall process. However, data availability is limited and hence, new technologies, measures or strategies can only be tested on a limited number of case studies. Owing to the specific boundary conditions and system properties of each single case study, results can hardly be generalized or transferred to other boundary conditions. virtual infrastructure benchmarking (VIBe) is a software tool which algorithmically generates virtual case studies (VCSs) for urban water systems. System descriptions needed for evaluation are extracted from VIBe whose parameters are based on real world case studies and literature. As a result VIBe writes Input files for water simulation software as EPANET and EPA SWMM. With such input files numerous simulations can be performed and the results can be benchmarked and analysed stochastically at a city scale. In this work the approach of VIBe is applied with parameters according to a section of the Inn valley and therewith 1,000 VCSs are generated and evaluated. A comparison of the VCSs with data of real world case studies shows that the real world case studies fit within the parameter ranges of the VCSs. Consequently, VIBe tackles the problem of limited availability of case study data.

Sign in / Sign up

Export Citation Format

Share Document